American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ALLO-647 for lymphodepletion in the allogeneic CAR T setting: Safety experience with ALLO-501/501A in patients (pts) with relapsed/refractory (r/r) large B-cell and follicular lymphomas
    Meeting Abstract

    Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; Eradat, H. A.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Valemetostat for relapsed or refractory peripheral T-cell lymphomas: Primary results from a phase 1 trial
    Meeting Abstract

    Jacobsen, E.; Maruyama, D.; Porcu, P.; Tobinai, K.; Allen, P. B.; Ishitsuka, K.; Tsukasaki, K.; Kusumoto, S.; Foss, F. M.; Yamauchi, N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A simple prediction model of outcomes after allogeneic hematopoietic stem cell transplant (HCT) in myelodysplastic syndromes using HCT-comorbidity index, cytogenetic risk, and platelet count
    Meeting Abstract

    Frumm, S. M.; Kim, H. T.; Kelkar, A. H.; Ho, V. T.; Gooptu, M.; Gibson, C. J.; Koreth, J.; Shapiro, R. M.; Romee, R.; Nikiforow, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Asciminib (ASC) in combination with Imatinib (IMA), nilotinib (NIL), or dasatinib (DAS) may be a potential treatment (Tx) option in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase (Ph + CML-CP/AP): Final results from the asciminib phase 1 study
    Meeting Abstract

    Cortes, J.; Lang, F.; Rea, D.; Hochhaus, A.; Breccia, M.; Goh, Y. T.; Heinrich, M. C.; Hughes, T. P.; Janssen, J. J. W. M.; le Coutre, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up
    Meeting Abstract

    Dhodapkar, M. V.; Alsina, M.; Berdeja, J. G.; Patel, K. K.; Richard, S.; Vij, R.; Leleu, X.; Egan, D. N.; Bergsagel, P. L.; Reshef, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Post-transplant cyclophosphamide eliminates disparity in GvHD-free, relapse-free survival and overall survival between 8/8 matched and 7/8 mismatched unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies
    Meeting Abstract

    Auletta, J. J.; Al Malki, M. M.; DeFor, T.; Shaffer, B. C.; Gooptu, M.; Bolanos-Meade, J.; Abboud, R.; Briggs, A. D.; Khimani, F.; Modi, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparable survival of treatment naive TP53 mutated acute myeloid leukemia treated with hypomethylating agent compared to hypomethylating agent plus venetoclax based therapy
    Meeting Abstract

    Badar, T.; Atallah, E. L.; Shallis, R. M.; Patel, A. A.; Correia, G. S. D. C.; Goldberg, A. D.; Saliba, A.; Bewersdorf, J. P.; Duvall, A. S.; Bradshaw, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) in children and young adults with low-risk classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo): Early results from the phase 2 KEYNOTE-667 study
    Meeting Abstract

    Roth, L. G.; Keller, F.; Toledo, M. M.; Castellino, S. M.; Forlenza, C. J.; Catalan, M. A.; Krystal, J.; Lamble, A.; Rao, A. V.; Morales, F. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • (131)I-apamistamab-led allogeneic hematopoietic cell transplant significantly improves overall survival in patients with TP53 mutated R/R AML
    Meeting Abstract

    Choe, H.; Tomlinson, B. K.; Gyurkocza, B.; Nath, R.; Seropian, S.; Litzow, M. R.; Abboud, C. N.; Stiff, P. J.; Abhyankar, S.; Foran, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical implications of TP53 mutations/allelic state in patients (Pts) with myelodysplastic syndromes/neoplasms (MDS) treated with hypomethylating agents (HMA)- a multicenter, retrospective analysis from the VALIDATE database
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save